Literature DB >> 1641149

Amyotrophic lateral sclerosis: increased solubility of skin collagen.

S Ono1, M Yamauchi.   

Abstract

We studied the solubility of skin collagen from six patients with amyotrophic lateral sclerosis (ALS) and six controls. The amount of collagen extracted with neutral salt solution was significantly greater in patients with ALS than in controls. In addition, there was a statistically significant increase in the proportion of collagen extracted from ALS patients with increased duration of illness. The collagen solubilized by pepsin and cyanogen bromide treatments was significantly higher in ALS patients than in controls, and its proportion was positively and significantly associated with duration of illness in ALS patients. These results indicate that the metabolism of skin collagen may be affected in the disease process of ALS, causing an increase in immature soluble collagen in the tissue, which is the opposite to that which occurs in the normal aging process.

Entities:  

Keywords:  NASA Discipline Musculoskeletal; Non-NASA Center

Mesh:

Substances:

Year:  1992        PMID: 1641149     DOI: 10.1212/wnl.42.8.1535

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Increased expression of insulin-like growth factor I in skin in amyotrophic lateral sclerosis.

Authors:  S Ono; J Hu; T Imai; N Shimizu; M Tsumura; H Nakagawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

Review 2.  Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach.

Authors:  Alok Kumar; Devlina Ghosh; R L Singh
Journal:  J Biomark       Date:  2013-03-14

3.  Aberrant Expression of Collagen Gene Family in the Brain Regions of Male Mice with Behavioral Psychopathologies Induced by Chronic Agonistic Interactions.

Authors:  Dmitry A Smagin; Anna G Galyamina; Irina L Kovalenko; Vladimir N Babenko; Natalia N Kudryavtseva
Journal:  Biomed Res Int       Date:  2019-04-28       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.